206 related articles for article (PubMed ID: 27530615)
21. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
[TBL] [Abstract][Full Text] [Related]
22. The p.G534E variant of
Kowalik A; Gąsior-Perczak D; Gromek M; Siołek M; Walczyk A; Pałyga I; Chłopek M; Kopczyński J; Mężyk R; Kowalska A; Góźdź S
Oncotarget; 2017 Aug; 8(35):58304-58308. PubMed ID: 28938557
[TBL] [Abstract][Full Text] [Related]
23. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
24. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
[TBL] [Abstract][Full Text] [Related]
25. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer.
Moses W; Weng J; Kebebew E
Thyroid; 2011 Apr; 21(4):367-71. PubMed ID: 21190444
[TBL] [Abstract][Full Text] [Related]
26. [A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update].
Valdes-Socin H; Palmeira L; Burlacu MC; Daly AF; Bours V; Beckers A
Rev Med Liege; 2016 Dec; 71(12):557-561. PubMed ID: 28387096
[TBL] [Abstract][Full Text] [Related]
27. Identification of
Marques IJ; Gomes I; Pojo M; Pires C; Moura MM; Cabrera R; Santos C; van IJcken WFJ; Teixeira MR; Ramalho JS; Leite V; Cavaco BM
Thyroid; 2021 Sep; 31(9):1366-1375. PubMed ID: 33906393
[No Abstract] [Full Text] [Related]
28. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
Hińcza K; Kowalik A; Kowalska A
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
[TBL] [Abstract][Full Text] [Related]
29. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
[TBL] [Abstract][Full Text] [Related]
30. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
[TBL] [Abstract][Full Text] [Related]
31. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
[TBL] [Abstract][Full Text] [Related]
32. Germ-line mutations in
Zhao Y; Yu T; Sun J; Wang F; Cheng C; He S; Chen L; Xie D; Fu L; Guan X; Yan A; Li Y; Miao G; Zhu X
Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326253
[TBL] [Abstract][Full Text] [Related]
33. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
Xing M
Clin Endocrinol (Oxf); 2005 Sep; 63(3):263-6. PubMed ID: 16117812
[TBL] [Abstract][Full Text] [Related]
34. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
[TBL] [Abstract][Full Text] [Related]
35. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
36. Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer.
Bauer AJ
Front Horm Res; 2013; 41():141-8. PubMed ID: 23652675
[TBL] [Abstract][Full Text] [Related]
37. Familial nonmedullary thyroid cancer: a case series in Iranian patients with a meta-review of case series.
Mohammadi Zaniani Z; Zeinalian M; Tabatabaiefar MA
Lab Med; 2023 Nov; ():. PubMed ID: 38007399
[TBL] [Abstract][Full Text] [Related]
38. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Cancer Control; 2006 Apr; 13(2):106-10. PubMed ID: 16735984
[TBL] [Abstract][Full Text] [Related]
39. Familial nonmedullary thyroid carcinoma.
Mazeh H; Sippel RS
Thyroid; 2013 Sep; 23(9):1049-56. PubMed ID: 23734600
[TBL] [Abstract][Full Text] [Related]
40. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.
Tomaz RA; Sousa I; Silva JG; Santos C; Teixeira MR; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2012 Dec; 77(6):926-33. PubMed ID: 22882326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
